Cassava Sciences Inc: Today’s Press Releases

Cassava Sciences Inc Press Release Related to Positive Biomarker Data 

Cassava Sciences Inc (SAVA) announced today, in a press release, positive biomarker data from an open-label study of simufilam, the Company’s investigational drug for the treatment of Alzheimer’s disease.

In a clinical study funded by the National Institutes of Health (NIH), simufilam significantly improved all measured biomarkers in patients with Alzheimer’s disease following 6 months of open-label treatment.

Biomarkers are objective biological data. There are no placebo effects.

Cerebrospinal fluid (CSF) biomarkers of disease pathology, t-tau, and p-tau181, decreased 38% and 18%, respectively.

CSF biomarkers of neurodegeneration, neurogranin, and Nfl, decreased 72% and 55%, respectively.

CSF biomarkers of neuroinflammation, sTREM2, and YKL-40, decreased 65% and 44.

CSF biomarker data were collected from 25 patients with mild-to-moderate Alzheimer’s disease who completed 6 months of simufilam treatment in an ongoing open-label study.

Leave a Reply